There are currently 1255 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
NCT05901545
Recruiting
This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the primary tumor (sentinel lymph nodes) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing surgery. The most important factor for survival for many cancer types is the presence of cancer that has spread to the lymph nodes (metastasis). Lymph node metastases in patients with head and neck cancer reduce... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer
NCT05945875
Recruiting
This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to detect disease in patients with head and neck cancer. 111In-panitumumab is an imaging agent made of a monoclonal antibody that has been labeled with a radioactive molecule called indium In 111. The ag... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810
Recruiting
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/09/2024
Locations: Sarah Cannon Research Institute/SCRI, Nashville, Tennessee
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Register for Updates
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895
Recruiting
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Sepsis, Septic Shock
Register for Updates
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
NCT02897063
Recruiting
The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt University Medical Center, and consists of 2 parts: a screening and 2 testing days. The total length of the study will be about 5 days. About 34 participants will be screened for the study.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
12/06/2024
Locations: Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Register for Updates
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
NCT05988710
Recruiting
The goal of this study is to compare the abuse potential of low-dose equianalgesic buccal buprenorphine to a commonly used full mu opioid receptor (MOR) agonist in a highly controlled experimental setting. This is a translational study in which healthy participants are phenotyped for psychosocial and Opioid-Use-Disorder-risk-related metrics. In a within-subjects crossover design, 60 participants will receive a standard postoperative oral oxycodone dose (10 mg), placebo, and 3 different doses of... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/06/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Analgesia, Abuse Opioids, Pain
Register for Updates
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
NCT06083480
Recruiting
This is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (OS); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (glycine + N-acetyl-cysteine(GlyNAC)) reduces oxidative stress and chronic post surgical pain (CPSP) in patients undergoing total knee arthroplasty (TKA).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/06/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Osteoarthritis, Knee, Total Knee Arthroplasty, Chronic Postsurgical Pain
Register for Updates
Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease
NCT05707663
Recruiting
The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: * Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? * Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations... Read More
Gender:
ALL
Ages:
Between 6 years and 30 years
Trial Updated:
12/04/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Register for Updates
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848
Recruiting
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Urology Associates, P.C., Nashville, Tennessee
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Nashville, Tennessee
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/24/2024
Locations: Sarah Cannon Research Institute, Pediatric Hematology & Oncology, Nashville, Tennessee
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
A Study of ZN-c3 in Patients With Ovarian Cancer
NCT04516447
Recruiting
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Site 0196, Nashville, Tennessee
Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates